PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
about
Heart failure with preserved ejection fraction: emerging drug strategiesBreakthrough in heart failure with preserved ejection fraction: are we there yet?Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"Redox regulation of cGMP-dependent protein kinase Iα in the cardiovascular systemAn official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicineNitric oxide synthases in heart failureCardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fractionErectile dysfunction in heart failure patients: a critical reappraisalTherapeutic potential of PDE modulation in treating heart diseaseExtending the translational potential of targeting NO/cGMP-regulated pathways in the CVSRight ventricular afterload and the role of nitric oxide metabolism in left-sided heart failureThe cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fractionTargeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of CardiologyPhosphodiesterases and cardiac cGMP: evolving roles and controversiesInhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytesClinical Phenotypes in Heart Failure With Preserved Ejection FractionThe emperor's new clothes: PDE5 and the heartSwimming-Induced Pulmonary Edema: Pathophysiology and Risk Reduction With Sildenafil.Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure modelShould there be sex-specific criteria for the diagnosis and treatment of heart failure?Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase IRole of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts.Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration.Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trialsStudy design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstruSex, drugs, and trial design: sex influences the heart and drug responsesPDE5 inhibitor efficacy is estrogen dependent in female heart disease.Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.PKG-1α leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension.Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy.Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects.Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodelingImpact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trialEffects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training.sGC{alpha}1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handlingThe role of phosphodiesterase inhibitors in the management of pulmonary vascular diseasesExercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy.Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operationEffects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
P2860
Q24595118-93EA774E-4A09-4D98-8FEE-E173BDFBDC16Q26771999-E1F84A2D-A682-4ABE-AC5D-21F2634506D2Q26785931-1B97395B-6C58-4F89-84D7-AF6174C38899Q26800060-5623A649-0FFC-436B-81E5-81EE5405CC2EQ26829758-DF540C49-FDEB-4347-8A82-0D3D60E2C279Q26830146-FFA4CDAB-7831-4D95-81E6-165A2346998DQ26853363-8D6FB36F-7D14-4934-8660-DE0C3C0EBB0DQ26853624-D6987CE4-E067-4F46-A9C8-759D392F0A4CQ27005761-13EA17CB-C5EA-41AD-95AB-3022E94E72C3Q27021649-79C2F6C2-1C15-4D4D-9B01-0B25655531BEQ27022359-01C5F654-0E22-44AE-BC1C-C0ADE28010B8Q27024279-8B987A1E-EC6D-4311-86D0-60B0C4F0EF5CQ27024879-E1B1ECB6-CD07-47D9-A713-593F0ED58F6BQ27692588-9220936E-0D65-4CBA-9EC2-3800D51648FCQ27967859-BBA0AD35-57F3-47CE-BC47-4D530AA702A5Q28073079-9E14FE7A-E678-4371-8D29-1806612EFA11Q28543897-C9DAC7BF-EC74-4EFB-80A9-1E258250022DQ30277332-D5AEAD6E-8D75-4941-8905-85A02EBC6127Q30385717-F9A680A3-6BD5-4125-8EDB-6003C1911475Q30442043-D6AB5AC3-BFD0-4E29-BC28-BF6F9BF16540Q30539041-C9FA373B-DB4A-4125-A810-60B1DA7021D4Q30575578-F3A2ADC1-89FD-4056-81E6-131213E6EC2DQ33594036-E28B41C5-61F0-465C-B133-8ACE69B8BBD3Q33791471-7D85DC50-48B2-4EA6-95F5-5D7A49A567B0Q33806226-2BF9305A-2E26-49E9-961C-5FBE0B657B3CQ33872473-0519502F-5EB5-4D45-B45B-6B9F2B34836EQ33872491-7F3A7E0E-7A79-465F-8378-5307F7FD5291Q33966155-DC9A7362-50D1-45E7-B7BB-D7BEF4405D3DQ34295259-0E070B39-3D11-4EFA-B46D-74907DF57098Q34315276-2B19AAFE-A3DF-409E-A885-1BB11C6053ACQ34364927-DC048971-B975-4761-8EC3-5EEE2D0BF0A3Q34421211-E2FAF0DC-A361-471F-BA9E-3A0843A6DB1FQ34634339-985050B1-AC80-40D8-87B2-648598385DA3Q34775696-9FCF9C7F-C0CC-4E76-A779-2BC9883AA01FQ34905015-558C5D26-C10B-45F2-A065-443862695533Q35087054-2449372B-7DBC-4F98-B6AD-9715EDA2C3C0Q35156618-5FC071F2-EDCD-42CE-830B-7C215891FA73Q35228404-B75391BF-A0C7-40D3-8BA6-0A4E1698C37CQ35233153-81900AD5-C2E1-48F9-8B24-A2365E9C8BA7Q35630046-20BDA716-94B9-444C-A678-B35479C7B743
P2860
PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
PDE5 inhibition with sildenafi ...... zed, placebo-controlled study.
@en
PDE5 inhibition with sildenafi ...... zed, placebo-controlled study.
@nl
type
label
PDE5 inhibition with sildenafi ...... zed, placebo-controlled study.
@en
PDE5 inhibition with sildenafi ...... zed, placebo-controlled study.
@nl
prefLabel
PDE5 inhibition with sildenafi ...... zed, placebo-controlled study.
@en
PDE5 inhibition with sildenafi ...... zed, placebo-controlled study.
@nl
P50
P921
P1476
PDE5 inhibition with sildenafi ...... zed, placebo-controlled study.
@en
P2093
Maurizio D Guazzi
P356
10.1161/CIRCHEARTFAILURE.110.944694
P577
2010-10-29T00:00:00Z